Global Maternal Mental Health Market Forecast
- Global maternal mental health market size to attain a valuation of US$40 Bn by the end of 2030
- Maternal mental health market value set to expand at a significant CAGR of 28% over 2023 - 2030
Market Analysis in Brief
The growth of the maternal meantal health is primarily driven by several factors, including increased government funding to reduce maternal mortality, a rise in the incidence of postpartum depression, growing awareness programs, and efforts to improve practices surrounding maternal mental health. The global significance of maternal mental health lies in its impact on mothers' wellbeing and the health and development of their children. The approximately four million live births annually in the US translates to around 600,000 reported cases of postpartum depression among them. Moreover, the maternal mental health market presents promising opportunities during the review period due to a favourable regulatory environment and reimbursement scenario.
Key Report Findings
- The market for maternal mental health will demonstrate an impressive growth in revenue between 2023 and 2030.
- Several key factors primarily drive the growth of the maternal mental health market. These include positive reimbursement scenarios, a rise in the incidence of postpartum depression (PPD), the implementation of growing awareness programs, and a strong and reliable healthcare infrastructure.
- Postpartum depression captured the largest market share in the maternal mental health market due to its prevalence and significant impact on postpartum mothers' mental wellbeing.
- Interpersonal therapy held a major market share in the maternal mental health market due to its effectiveness in addressing relationship-based stressors and improving maternal wellbeing during the perinatal period.
- North America will continue to lead its way, whereas Asia Pacific's maternal mental health market will experience the strongest growth till 2030.
Growth Drivers
Growing Government Funds Targeting Reduced Maternal Mortality
Growing government funds aimed at reducing maternal mortality have significantly impacted the maternal mental health market. By investing in mental health services and support for pregnant and postpartum women, governments aim to mitigate the risk of maternal mental health disorders and improve overall maternal health outcomes.
The increased funding has led to expanding maternal mental health services, including screening and early detection of mental health issues, counseling and therapy services, and the establishment of specialised clinics and support groups. Additionally, government-funded awareness campaigns have helped reduce the stigma surrounding maternal mental health, encouraging more women to seek help when facing emotional challenges during and after pregnancy. As a result, the maternal mental health market has witnessed growth and greater recognition, with more healthcare providers offering specialised services to cater to the needs of pregnant and postpartum women.
By addressing maternal mental health concerns, governments aim to enhance maternal care and reduce maternal mortality rates, making it a critical driver in the growth of the maternal mental health market.
Growing Incidences of Postpartum Depression
The growing incidences of postpartum depression (PPD) have become a significant driving force behind the expansion of the maternal mental health market. PPD is a prevalent mental health condition that affects many new mothers after childbirth. With increasing awareness and improved screening measures, more cases of PPD are being identified and addressed, leading to a higher demand for maternal mental health services.
Healthcare providers and policymakers have recognised the importance of early detection and intervention for PPD to prevent its potential long-term impact on both the mother and the child's wellbeing, which has further fueled the growth of the maternal mental health market.
As the societal stigma surrounding mental health issues continues to decrease, more women seek help for PPD, increasing demand for specialised mental healthcare during the perinatal period. This growing patient population has led to the establishment of dedicated maternal mental health clinics, the training of healthcare professionals in evidence-based PPD interventions, and the development of innovative therapies tailored to address the unique challenges faced by new mothers.
Additionally, advocacy groups and organisations have played a crucial role in raising awareness about PPD and its effects on maternal health, driving increased funding and support for maternal mental health services. The growing incidences of postpartum depression have become a central driver in the expansion and recognition of the maternal mental health market.
Growth Challenges
Mental Health Workforce Shortage
The maternal mental health market faces significant constraints due to the ongoing mental health workforce shortage. There is an urgent need for qualified experts who focus on maternal mental health due to the rising demand for mental health treatments during the perinatal period.
However, there is a dearth of these field-experienced psychiatrists, psychologists, social workers, and other mental health professionals. Long wait times for appointments, restricted access to specialised treatment, and difficulties delivering prompt interventions for pregnant and postpartum women facing mental health disorders are all caused by this scarcity.
The unique complexities of maternal mental healthcare exacerbate the mental health workforce shortage. Addressing perinatal mental health requires sensitivity to the specific needs and challenges faced by new mothers, as well as a comprehensive understanding of the impact of mental health on both the mother's and the child's wellbeing. Without an adequate workforce, many pregnant and postpartum women may not receive the appropriate level of care and support required, leading to potential adverse outcomes for maternal and infant health.
Furthermore, the shortage also affects the capacity of healthcare facilities and clinics to offer specialised maternal mental health services, hindering the market's growth and the overall quality of care available to women during this critical phase of their lives. To address this restraint, efforts are needed to invest in mental health workforce development, incentivise practitioners to specialise in maternal mental health and promote research and training opportunities to build a more robust workforce that adequately supports the needs of pregnant and postpartum women.
Overview of Key Segments
Postpartum Depression Accounts for the Largest Share of Market Pie
Postpartum depression is a prevalent mental health condition that affects many women after childbirth. The condition involves sadness, anxiety, and exhaustion, which can interfere with a mother's ability to care for herself and her baby. Given its prevalence and potential impact on both the mother's and the child's wellbeing, there has been a growing focus on addressing and treating PPD in recent years.
Healthcare providers, policymakers, and advocacy groups have been raising awareness about postpartum depression, leading to increased screening and early detection of the condition. As a result, more women seek help and treatment for PPD, which drives the demand for maternal mental health services in this specific disease indication.
Furthermore, specialised programs and support groups have expanded dedicated to PPD treatment, emphasizing the significance of addressing this particular mental health concern, potentially contributing to its prominence within the maternal mental health market.
Recognising the far-reaching consequences of untreated PPD on maternal-infant bonding, child development, and overall family wellbeing has also spurred research into effective therapeutic interventions. The emphasis on developing and offering comprehensive treatment options for postpartum depression might further contribute to its leading position in the maternal mental health market.
Interpersonal Therapy Sought-after
Interpersonal therapy (IPT) has been extensively researched and shown to be effective in treating various mental health disorders, including depression and anxiety, which are prevalent among pregnant and postpartum women. The evidence-based nature of IPT might have led to its recognition and endorsement by mental health professionals and healthcare organisations, potentially increasing its utilisation in the maternal mental health field.
Secondly, the focus of IPT on interpersonal relationships and addressing life challenges that can arise during the perinatal period could be particularly relevant for new mothers. Pregnancy and the postpartum phase often change family dynamics, relationships, and social support systems, impacting a woman's mental wellbeing. IPT's emphasis on improving communication and resolving interpersonal issues may resonate with many women seeking help for maternal mental health concerns, making it a preferred choice in therapy.
While these factors suggest that IPT could be a valuable therapeutic approach in the maternal mental health market, it is essential to note that other therapeutic modalities, such as cognitive-behavioural therapy (CBT), psychodynamic therapy, and supportive counseling, may also play significant roles in addressing perinatal mental health issues.
Growth Opportunities Across Regions
North America Spearheads with Increased Accessibility of Specialised Care, Counseling Services, and Support Groups
North America held the largest maternal mental health market share for several reasons. Firstly, the region boasts advanced healthcare infrastructure, including well-established healthcare facilities, a strong network of hospitals and clinics, and easy access to mental health services. This accessibility has significantly increased awareness about maternal mental health issues, leading to more women seeking help and treatment for conditions such as postpartum depression, anxiety, and mood disorders.
Secondly, North America has witnessed a growing trend of prioritising maternal mental health in the healthcare system. Government initiatives, healthcare policies, and private sector investments have focused on improving maternal mental health outcomes and increasing the availability of specialised care, counseling services, and support groups for new mothers. The region's emphasis on mental health awareness and destigmatisation has encouraged more women to come forward and seek assistance for their mental health challenges during the perinatal period.
Asia Pacific Gains from Growing Maternal Mental Health Awareness
The Asia Pacific maternal mental health market has been identified as the fastest-growing market for several compelling reasons. Firstly, the region has witnessed a significant rise in awareness and recognition of maternal mental health issues. Traditionally, mental health has been stigmatised in some parts of Asia. There has still been a notable shift in attitudes in recent years, with greater efforts made to raise awareness about perinatal mental health challenges. This increased awareness has led to more women seeking help for mental health conditions during and after pregnancy, creating a higher demand for maternal mental health services and contributing to the market's rapid growth.
Moreover, the Asia Pacific region has been experiencing economic growth and development, resulting in improved healthcare infrastructure and access to medical facilities. As countries in the region continue to advance their healthcare systems, there has been a greater focus on women's health, including maternal mental health.
Governments and private healthcare providers have been investing in specialised maternal mental health services, such as counseling centers, perinatal psychiatric units, and support groups, to cater to the needs of pregnant and postpartum women. This enhanced focus on maternal mental healthcare has fueled market growth and positioned the Asia Pacific region as a key player in addressing perinatal mental health challenges.
Maternal Mental Health Market: Competitive Landscape
Some of the leading players at the forefront in the maternal mental health market space include Lipocine, Inc., Pfizer, Inc., Viatris, Inc., Bold Health, GlaxoSmithKline Inc., Alembic Pharmaceuticals Limited, Mallinckrodt, Inc., Sage Therapeutics, Inc., Bausch Health Companies Inc., and Magellan Health, Inc.
Recent Notable Developments
In August 2023, Sage Therapeutics, Inc. announced the U.S. Food and Drug Administration approval of Zurzuvae (zuranolone), the first oral medication in the form of pill, indicated to treat postpartum depression (PPD) in adults.
In May 2023, Canopie and Uber joined forces to address parental mental health challenges, encouraging open discussions about sensitive topics. Uber EMEA parents will receive complimentary access to Canopie's evidence-based platform through this innovative partnership. The platform offers tailored clinical therapeutic techniques, specifically targeting new parents' unique mental and emotional struggles. With a multi-language interface, it includes real-life accounts from other parents and practical tips on navigating common parenting hurdles, such as balancing work commitments while preserving a sense of identity. Furthermore, the platform is equipped to provide emergency support for parents in crises, ensuring a comprehensive and supportive mental health resource for Uber EMEA's user base.
In November 2022, Aeroflow Breastpumps has recently announced a strategic partnership with Canopie, aiming to enhance maternal health outcomes. As part of this collaboration, customers of Aeroflow Breastpumps, a prominent breast pump distributor and breastfeeding resource center, will gain access to free, clinically-effective, and on-demand mental health support tools. These resources are designed to assist in reducing postpartum stress, anxiety, and depression, providing new mothers with convenient access to support from the comfort of their own homes.
In September 2022, Lipocine, Inc. a biopharmaceutical company focused on developing innovative products targeting large addressable markets with significant unmet needs to treat central nervous system and metabolic disorders, announced that the U.S. Food and Drug Administration has agreed with Lipocine’s proposal for establishing the efficacy of LPCN 1154 through a single pivotal pharmacokinetic bridge to an approved IV infusion brexanolone via a 505(b)(2) NDA filing. Lipocine plans additional work in parallel to pursue a well-differentiated label.
Global Maternal Mental Health Market is Segmented as Below:
By Disease Indication
- Postpartum Depression
- Dysthymia
- Pregnancy and Postpartum General Anxiety
- Pregnancy and Postpartum OCD
- Birth-Related PTSD
- Others
By Therapy
- Antidepressants
- Selective serotonin reuptake inhibitors (SSRIs)
- Tricyclic antidepressants (TCAs)
- Other
- Interpersonal Psychotherapy (IPT)
- Cognitive Behavioural Therapy (CBT)
- Other
By Geographic Coverage
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Turkey
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Egypt
- Nigeria
- Rest of the Middle East & Africa
1. Executive Summary
1.1. Global Maternal Mental Health Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. Covid-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Maternal Mental Health Market Outlook, 2018 - 2030
3.1. Global Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Postpartum Depression
3.1.1.2. Dysthymia
3.1.1.3. Pregnancy and Postpartum General Anxiety
3.1.1.4. Pregnancy and Postpartum OCD
3.1.1.5. Birth-Related PTSD
3.1.1.6. Others
3.2. Global Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Antidepressants
3.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
3.2.1.1.2. Tricyclic antidepressants (TCAs)
3.2.1.1.3. Other
3.2.1.2. Interpersonal Psychotherapy (IPT)
3.2.1.3. Cognitive Behavioural Therapy (CBT)
3.2.1.4. Other
3.3. Global Maternal Mental Health Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Maternal Mental Health Market Outlook, 2018 - 2030
4.1. North America Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Postpartum Depression
4.1.1.2. Dysthymia
4.1.1.3. Pregnancy and Postpartum General Anxiety
4.1.1.4. Pregnancy and Postpartum OCD
4.1.1.5. Birth-Related PTSD
4.1.1.6. Others
4.2. North America Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Antidepressants
4.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
4.2.1.1.2. Tricyclic antidepressants (TCAs)
4.2.1.1.3. Other
4.2.1.2. Interpersonal Psychotherapy (IPT)
4.2.1.3. Cognitive Behavioural Therapy (CBT)
4.2.1.4. Other
4.2.2. Market Attractiveness Analysis
4.3. North America Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. U.S. Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
4.3.1.2. U.S. Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
4.3.1.3. Canada Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
4.3.1.4. Canada Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Maternal Mental Health Market Outlook, 2018 - 2030
5.1. Europe Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Postpartum Depression
5.1.1.2. Dysthymia
5.1.1.3. Pregnancy and Postpartum General Anxiety
5.1.1.4. Pregnancy and Postpartum OCD
5.1.1.5. Birth-Related PTSD
5.1.1.6. Others
5.2. Europe Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Antidepressants
5.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
5.2.1.1.2. Tricyclic antidepressants (TCAs)
5.2.1.1.3. Other
5.2.1.2. Interpersonal Psychotherapy (IPT)
5.2.1.3. Cognitive Behavioural Therapy (CBT)
5.2.1.4. Other
5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. Germany Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.2. Germany Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.3. U.K. Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.4. U.K. Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.5. France Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.6. France Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.7. Italy Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.8. Italy Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.9. Turkey Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.10. Turkey Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.11. Russia Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.12. Russia Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
5.3.1.13. Rest Of Europe Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
5.3.1.14. Rest Of Europe Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
5.3.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Maternal Mental Health Market Outlook, 2018 - 2030
6.1. Asia Pacific Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
6.1.1. Key Highlights
6.1.1.1. Postpartum Depression
6.1.1.2. Dysthymia
6.1.1.3. Pregnancy and Postpartum General Anxiety
6.1.1.4. Pregnancy and Postpartum OCD
6.1.1.5. Birth-Related PTSD
6.1.1.6. Others
6.2. Asia Pacific Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Antidepressants
6.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
6.2.1.1.2. Tricyclic antidepressants (TCAs)
6.2.1.1.3. Other
6.2.1.2. Interpersonal Psychotherapy (IPT)
6.2.1.3. Cognitive Behavioural Therapy (CBT)
6.2.1.4. Other
6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. China Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.2. China Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.1.3. Japan Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.4. Japan Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.1.5. South Korea Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.6. South Korea Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.1.7. India Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.8. India Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.1.9. Southeast Asia Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.10. Southeast Asia Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.1.11. Rest of Asia Pacific Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
6.3.1.12. Rest of Asia Pacific Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
6.3.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Maternal Mental Health Market Outlook, 2018 - 2030
7.1. Latin America Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Postpartum Depression
7.1.1.2. Dysthymia
7.1.1.3. Pregnancy and Postpartum General Anxiety
7.1.1.4. Pregnancy and Postpartum OCD
7.1.1.5. Birth-Related PTSD
7.1.1.6. Others
7.2. Latin America Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Antidepressants
7.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
7.2.1.1.2. Tricyclic antidepressants (TCAs)
7.2.1.1.3. Other
7.2.1.2. Interpersonal Psychotherapy (IPT)
7.2.1.3. Cognitive Behavioural Therapy (CBT)
7.2.1.4. Other
7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
7.3.1. Key Highlights
7.3.1.1. Brazil Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
7.3.1.2. Brazil Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
7.3.1.3. Mexico Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
7.3.1.4. Mexico Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
7.3.1.5. Argentina Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
7.3.1.6. Argentina Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
7.3.1.7. Rest of Latin America Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
7.3.1.8. Rest of Latin America Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
7.3.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Maternal Mental Health Market Outlook, 2018 - 2030
8.1. Middle East & Africa Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Postpartum Depression
8.1.1.2. Dysthymia
8.1.1.3. Pregnancy and Postpartum General Anxiety
8.1.1.4. Pregnancy and Postpartum OCD
8.1.1.5. Birth-Related PTSD
8.1.1.6. Others
8.2. Middle East & Africa Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Antidepressants
8.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
8.2.1.1.2. Tricyclic antidepressants (TCAs)
8.2.1.1.3. Other
8.2.1.2. Interpersonal Psychotherapy (IPT)
8.2.1.3. Cognitive Behavioural Therapy (CBT)
8.2.1.4. Other
8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
8.3.1. Key Highlights
8.3.1.1. GCC Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
8.3.1.2. GCC Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
8.3.1.3. South Africa Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
8.3.1.4. South Africa Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
8.3.1.5. Egypt Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
8.3.1.6. Egypt Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
8.3.1.7. Nigeria Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
8.3.1.8. Nigeria Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
8.3.1.9. Rest of Middle East & Africa Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
8.3.1.10. Rest of Middle East & Africa Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
8.3.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Disease Indication vs Application Heatmap
9.2. Manufacturer vs Application Heatmap
9.3. Company Market Share Analysis, 2022
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Pfizer, Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Lipocine, Inc.
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Viatris Inc.
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. GlaxoSmithKline plc
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Alembic Pharmaceuticals Limited
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Mallinckrodt, Inc.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Sage Therapeutics, Inc.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Bold Health
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Bausch Health Companies Inc.
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Magellan Health, Inc.
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
|
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
 |
2022 |
 |
2018 - 2022 |
 |
2023 - 2030 |
Value: US$ Million |
|
REPORT FEATURES |
DETAILS |
|
Disease Indication Coverage |
|
|
Therapy Coverage |
|
|
Geographical Coverage |
|
|
Leading Companies |
|
|
Report Highlights |
Key Market Indicators, Macro-micro economic impact analysis, Technological Roadmap, Key Trends, Driver, Restraints, and Future Opportunities & Revenue Pockets, Porter’s 5 Forces Analysis, Historical Trend (2019-2021), Market Estimates and Forecast, Market Dynamics, Industry Trends, Competition Landscape, Category, Region, Country-wise Trends & Analysis, COVID-19 Impact Analysis (Demand and Supply Chain) |
Quality assured
